Bilastina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bilastina" in Italian language version.

refsWebsite

Global rank Italian rank

21nih.gov

4^th place

9^th place

18doi.org

2^nd place

7^th place

14oadoi.org

799^th place

22^nd place

4archive.org

6^th place

8^th place

1clinicaltrials.gov

5,225^th place

5,296^th place

archive.org

P. Kuna, C. Bachert; Z. Nowacki; P. van Cauwenberge; I. Agache; L. Fouquert; A. Roger; A. Sologuren; R. Valiente; P. Clement; V. van Dist, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study., in Clin Exp Allergy, vol. 39, n. 9, Sep 2009, pp. 1338-47, DOI:10.1111/j.1365-2222.2009.03257.x, PMID 19438584.
GK. Dresser, DG. Bailey; BF. Leake; UI. Schwarz; PA. Dawson; DJ. Freeman; RB. Kim, Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine., in Clin Pharmacol Ther, vol. 71, n. 1, Jan 2002, pp. 11-20, DOI:10.1067/mcp.2002.121152, PMID 11823753.
GK. Dresser, RB. Kim; DG. Bailey, Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides., in Clin Pharmacol Ther, vol. 77, n. 3, Mar 2005, pp. 170-7, DOI:10.1016/j.clpt.2004.10.005, PMID 15735611.
C. García-Gea, J. Martínez-Colomer; RM. Antonijoan; R. Valiente; MJ. Barbanoj, Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments., in J Clin Psychopharmacol, vol. 28, n. 6, Dec 2008, pp. 675-85, DOI:10.1097/JCP.0b013e31818b2091, PMID 19011437.

clinicaltrials.gov

Human Mass Balance Study With Bilastine - Full Text View - ClinicalTrials.gov, su clinicaltrials.gov. URL consultato il 28 settembre 2012.

doi.org

dx.doi.org

J. Bousquet, I. Ansótegui; GW. Canonica; T. Zuberbier; CE. Baena-Cagnani; C. Bachert; AA. Cruz; SN. González; P. Kuna; M. Morais-Almeida; J. Mullol, Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 131-9, DOI:10.1185/03007995.2011.648263, PMID 22149770.
I. Jáuregui, E. García-Lirio; AM. Soriano; PM. Gamboa; I. Antépara, An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria., in Expert Rev Clin Immunol, vol. 8, n. 1, Jan 2012, pp. 33-41, DOI:10.1586/eci.11.87, PMID 22149338.
MK. Church, Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans., in Inflamm Res, vol. 60, n. 12, Dec 2011, pp. 1107-12, DOI:10.1007/s00011-011-0373-y, PMID 21874559.
C. Graff, JJ. Struijk; JK. Kanters; MP. Andersen; E. Toft; B. Tyl, Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study., in Clin Drug Investig, vol. 32, n. 5, maggio 2012, pp. 339-51, DOI:10.2165/11599270-000000000-00000, PMID 22393898.
J. Sastre, J. Mullol; A. Valero; R. Valiente; RG. Arnolt; R. Bailleau; C. Crisci; A. de Falco; A. Gandur; M. Gómez; E. Jares, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 121-30, DOI:10.1185/03007995.2011.640667, PMID 22077106.
P. Kuna, C. Bachert; Z. Nowacki; P. van Cauwenberge; I. Agache; L. Fouquert; A. Roger; A. Sologuren; R. Valiente; P. Clement; V. van Dist, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study., in Clin Exp Allergy, vol. 39, n. 9, Sep 2009, pp. 1338-47, DOI:10.1111/j.1365-2222.2009.03257.x, PMID 19438584.
ML. Lucero, A. Gonzalo; A. Ganza; N. Leal; I. Soengas; E. Ioja; S. Gedey; M. Jahic; D. Bednarczyk, Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 8-17, DOI:10.3109/01480545.2012.682653, PMID 22616811.
ML. Lucero, A. Gonzalo; R. Mumford; M. Betanzos; A. Alejandro, An overview of bilastine metabolism during preclinical investigations., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 18-24, DOI:10.3109/01480545.2012.682651, PMID 22616812.
N. Jauregizar, L. de la Fuente; ML. Lucero; A. Sologuren; N. Leal; M. Rodríguez, Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine., in Clin Pharmacokinet, vol. 48, n. 8, 2009, pp. 543-54, DOI:10.2165/11317180-000000000-00000, PMID 19705924.
Bilastine in allergic rhinoconjunctivitis and urticaria - Bachert - 2010 - Allergy - Wiley Online Library, DOI:10.1111/j.1398-9995.2010.02404.x.
DG. Bailey, Fruit juice inhibition of uptake transport: a new type of food-drug interaction., in Br J Clin Pharmacol, vol. 70, n. 5, Nov 2010, pp. 645-55, DOI:10.1111/j.1365-2125.2010.03722.x, PMID 21039758.
GK. Dresser, DG. Bailey; BF. Leake; UI. Schwarz; PA. Dawson; DJ. Freeman; RB. Kim, Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine., in Clin Pharmacol Ther, vol. 71, n. 1, Jan 2002, pp. 11-20, DOI:10.1067/mcp.2002.121152, PMID 11823753.
GK. Dresser, RB. Kim; DG. Bailey, Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides., in Clin Pharmacol Ther, vol. 77, n. 3, Mar 2005, pp. 170-7, DOI:10.1016/j.clpt.2004.10.005, PMID 15735611.
MK. Church, Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 779-93, DOI:10.1517/14740338.2011.604029, PMID 21831011.
C. Bachert, P. Kuna; F. Sanquer; P. Ivan; V. Dimitrov; MM. Gorina; P. van de Heyning; A. Loureiro; EP. Hamans; P. Cauwenberge; T. Belder, Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients., in Allergy, vol. 64, n. 1, Jan 2009, pp. 158-65, DOI:10.1111/j.1398-9995.2008.01813.x, PMID 19132976.
T. Zuberbier, A. Oanta; E. Bogacka; I. Medina; F. Wesel; P. Uhl; I. Antépara; I. Jáuregui; R. Valiente; R. Baillieau; J. Ramos, Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study., in Allergy, vol. 65, n. 4, Apr 2010, pp. 516-28, DOI:10.1111/j.1398-9995.2009.02217.x, PMID 19860762.
C. García-Gea, J. Martínez-Colomer; RM. Antonijoan; R. Valiente; MJ. Barbanoj, Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments., in J Clin Psychopharmacol, vol. 28, n. 6, Dec 2008, pp. 675-85, DOI:10.1097/JCP.0b013e31818b2091, PMID 19011437.
S. Conen, EL. Theunissen; AC. Van Oers; R. Valiente; JG. Ramaekers, Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers., in J Psychopharmacol, vol. 25, n. 11, Nov 2011, pp. 1517-23, DOI:10.1177/0269881110382467, PMID 20855350.

nih.gov

ncbi.nlm.nih.gov

R. Corcóstegui, L. Labeaga; A. Innerárity; A. Berisa; A. Orjales, Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity., in Drugs R D, vol. 6, n. 6, 2005, pp. 371-84, PMID 16274260.
I. Jáuregui, J. Bartra; A. del Cuvillo; I. Dávila; M. Ferrer; J. Montoro; J. Mullol; J. Sastre; A. Valero, Bilastine and quality of life., in J Investig Allergol Clin Immunol, 21 Suppl 3, 2011, pp. 16-23, PMID 22185046.
J. Bousquet, I. Ansótegui; GW. Canonica; T. Zuberbier; CE. Baena-Cagnani; C. Bachert; AA. Cruz; SN. González; P. Kuna; M. Morais-Almeida; J. Mullol, Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 131-9, DOI:10.1185/03007995.2011.648263, PMID 22149770.
I. Jáuregui, E. García-Lirio; AM. Soriano; PM. Gamboa; I. Antépara, An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria., in Expert Rev Clin Immunol, vol. 8, n. 1, Jan 2012, pp. 33-41, DOI:10.1586/eci.11.87, PMID 22149338.
J. Bartra, J. Mullol; J. Montoro; I. Jáuregui; A. del Cuvillos; I. Dávila; M. Ferrer; J. Sastre; A. Valero, Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis., in J Investig Allergol Clin Immunol, 21 Suppl 3, 2011, pp. 24-33, PMID 22185047.
MK. Church, Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans., in Inflamm Res, vol. 60, n. 12, Dec 2011, pp. 1107-12, DOI:10.1007/s00011-011-0373-y, PMID 21874559.
C. Graff, JJ. Struijk; JK. Kanters; MP. Andersen; E. Toft; B. Tyl, Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study., in Clin Drug Investig, vol. 32, n. 5, maggio 2012, pp. 339-51, DOI:10.2165/11599270-000000000-00000, PMID 22393898.
I. Dávila, J. Sastre; J. Mullol; J. Montoro; I. Jáuregui; M. Ferrer; A. del Cuvillo; J. Bartra; A. Valero, Effect of bilastine upon nasal obstruction., in J Investig Allergol Clin Immunol, 21 Suppl 3, 2011, pp. 2-8, PMID 22185044.
J. Sastre, J. Mullol; A. Valero; R. Valiente; RG. Arnolt; R. Bailleau; C. Crisci; A. de Falco; A. Gandur; M. Gómez; E. Jares, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 121-30, DOI:10.1185/03007995.2011.640667, PMID 22077106.
P. Kuna, C. Bachert; Z. Nowacki; P. van Cauwenberge; I. Agache; L. Fouquert; A. Roger; A. Sologuren; R. Valiente; P. Clement; V. van Dist, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study., in Clin Exp Allergy, vol. 39, n. 9, Sep 2009, pp. 1338-47, DOI:10.1111/j.1365-2222.2009.03257.x, PMID 19438584.
ML. Lucero, A. Gonzalo; A. Ganza; N. Leal; I. Soengas; E. Ioja; S. Gedey; M. Jahic; D. Bednarczyk, Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 8-17, DOI:10.3109/01480545.2012.682653, PMID 22616811.
ML. Lucero, A. Gonzalo; R. Mumford; M. Betanzos; A. Alejandro, An overview of bilastine metabolism during preclinical investigations., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 18-24, DOI:10.3109/01480545.2012.682651, PMID 22616812.
N. Jauregizar, L. de la Fuente; ML. Lucero; A. Sologuren; N. Leal; M. Rodríguez, Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine., in Clin Pharmacokinet, vol. 48, n. 8, 2009, pp. 543-54, DOI:10.2165/11317180-000000000-00000, PMID 19705924.
DG. Bailey, Fruit juice inhibition of uptake transport: a new type of food-drug interaction., in Br J Clin Pharmacol, vol. 70, n. 5, Nov 2010, pp. 645-55, DOI:10.1111/j.1365-2125.2010.03722.x, PMID 21039758.
GK. Dresser, DG. Bailey; BF. Leake; UI. Schwarz; PA. Dawson; DJ. Freeman; RB. Kim, Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine., in Clin Pharmacol Ther, vol. 71, n. 1, Jan 2002, pp. 11-20, DOI:10.1067/mcp.2002.121152, PMID 11823753.
GK. Dresser, RB. Kim; DG. Bailey, Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides., in Clin Pharmacol Ther, vol. 77, n. 3, Mar 2005, pp. 170-7, DOI:10.1016/j.clpt.2004.10.005, PMID 15735611.
MK. Church, Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 779-93, DOI:10.1517/14740338.2011.604029, PMID 21831011.
C. Bachert, P. Kuna; F. Sanquer; P. Ivan; V. Dimitrov; MM. Gorina; P. van de Heyning; A. Loureiro; EP. Hamans; P. Cauwenberge; T. Belder, Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients., in Allergy, vol. 64, n. 1, Jan 2009, pp. 158-65, DOI:10.1111/j.1398-9995.2008.01813.x, PMID 19132976.
T. Zuberbier, A. Oanta; E. Bogacka; I. Medina; F. Wesel; P. Uhl; I. Antépara; I. Jáuregui; R. Valiente; R. Baillieau; J. Ramos, Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study., in Allergy, vol. 65, n. 4, Apr 2010, pp. 516-28, DOI:10.1111/j.1398-9995.2009.02217.x, PMID 19860762.
C. García-Gea, J. Martínez-Colomer; RM. Antonijoan; R. Valiente; MJ. Barbanoj, Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments., in J Clin Psychopharmacol, vol. 28, n. 6, Dec 2008, pp. 675-85, DOI:10.1097/JCP.0b013e31818b2091, PMID 19011437.
S. Conen, EL. Theunissen; AC. Van Oers; R. Valiente; JG. Ramaekers, Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers., in J Psychopharmacol, vol. 25, n. 11, Nov 2011, pp. 1517-23, DOI:10.1177/0269881110382467, PMID 20855350.

oadoi.org

J. Bousquet, I. Ansótegui; GW. Canonica; T. Zuberbier; CE. Baena-Cagnani; C. Bachert; AA. Cruz; SN. González; P. Kuna; M. Morais-Almeida; J. Mullol, Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 131-9, DOI:10.1185/03007995.2011.648263, PMID 22149770.
I. Jáuregui, E. García-Lirio; AM. Soriano; PM. Gamboa; I. Antépara, An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria., in Expert Rev Clin Immunol, vol. 8, n. 1, Jan 2012, pp. 33-41, DOI:10.1586/eci.11.87, PMID 22149338.
MK. Church, Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans., in Inflamm Res, vol. 60, n. 12, Dec 2011, pp. 1107-12, DOI:10.1007/s00011-011-0373-y, PMID 21874559.
C. Graff, JJ. Struijk; JK. Kanters; MP. Andersen; E. Toft; B. Tyl, Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study., in Clin Drug Investig, vol. 32, n. 5, maggio 2012, pp. 339-51, DOI:10.2165/11599270-000000000-00000, PMID 22393898.
J. Sastre, J. Mullol; A. Valero; R. Valiente; RG. Arnolt; R. Bailleau; C. Crisci; A. de Falco; A. Gandur; M. Gómez; E. Jares, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis., in Curr Med Res Opin, vol. 28, n. 1, Jan 2012, pp. 121-30, DOI:10.1185/03007995.2011.640667, PMID 22077106.
ML. Lucero, A. Gonzalo; A. Ganza; N. Leal; I. Soengas; E. Ioja; S. Gedey; M. Jahic; D. Bednarczyk, Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 8-17, DOI:10.3109/01480545.2012.682653, PMID 22616811.
ML. Lucero, A. Gonzalo; R. Mumford; M. Betanzos; A. Alejandro, An overview of bilastine metabolism during preclinical investigations., in Drug Chem Toxicol, 35 Suppl 1, Jun 2012, pp. 18-24, DOI:10.3109/01480545.2012.682651, PMID 22616812.
N. Jauregizar, L. de la Fuente; ML. Lucero; A. Sologuren; N. Leal; M. Rodríguez, Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine., in Clin Pharmacokinet, vol. 48, n. 8, 2009, pp. 543-54, DOI:10.2165/11317180-000000000-00000, PMID 19705924.
Bilastine in allergic rhinoconjunctivitis and urticaria - Bachert - 2010 - Allergy - Wiley Online Library, DOI:10.1111/j.1398-9995.2010.02404.x.
DG. Bailey, Fruit juice inhibition of uptake transport: a new type of food-drug interaction., in Br J Clin Pharmacol, vol. 70, n. 5, Nov 2010, pp. 645-55, DOI:10.1111/j.1365-2125.2010.03722.x, PMID 21039758.
MK. Church, Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria., in Expert Opin Drug Saf, vol. 10, n. 5, Sep 2011, pp. 779-93, DOI:10.1517/14740338.2011.604029, PMID 21831011.
C. Bachert, P. Kuna; F. Sanquer; P. Ivan; V. Dimitrov; MM. Gorina; P. van de Heyning; A. Loureiro; EP. Hamans; P. Cauwenberge; T. Belder, Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients., in Allergy, vol. 64, n. 1, Jan 2009, pp. 158-65, DOI:10.1111/j.1398-9995.2008.01813.x, PMID 19132976.
T. Zuberbier, A. Oanta; E. Bogacka; I. Medina; F. Wesel; P. Uhl; I. Antépara; I. Jáuregui; R. Valiente; R. Baillieau; J. Ramos, Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study., in Allergy, vol. 65, n. 4, Apr 2010, pp. 516-28, DOI:10.1111/j.1398-9995.2009.02217.x, PMID 19860762.
S. Conen, EL. Theunissen; AC. Van Oers; R. Valiente; JG. Ramaekers, Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers., in J Psychopharmacol, vol. 25, n. 11, Nov 2011, pp. 1517-23, DOI:10.1177/0269881110382467, PMID 20855350.